From Diagnosis to Discovery: How Biospecimens Power Rare Disease Therapeutics

Photo credit: CDC/ Dr. David M. Morens, Dr. Steve Thacker

The journey from understanding a rare disease’s molecular basis to delivering effective therapies to patients spans years or decades, requiring coordinated efforts across basic science, translational research, preclinical development, clinical trials, and regulatory approval. At every stage of this therapeutic development continuum, high-quality biospecimens serve as essential tools enabling discoveries, validating hypotheses, and de-risking development decisions. For rare diseases affecting small patient populations where traditional clinical development pathways face unique challenges, biospecimen-based research becomes even more critical, often determining whether therapeutic programs can advance or stall due to insufficient biological understanding or inadequate validation tools.

Recent analyses reveal that approximately 95% of rare diseases still lack approved therapies despite decades of research investment. While scientific challenges certainly contribute to this gap, limitations in accessing appropriate biospecimens for research, validation, and clinical development represent significant obstacles that innovative biospecimen collection strategies can help overcome. Understanding how biospecimens power therapeutic development across the complete research continuum illuminates where strategic investments in biospecimen infrastructure can accelerate progress toward treatments for currently untreatable rare conditions.

Mechanistic Research: Unlocking Disease Biology

Therapeutic development begins with fundamental understanding of disease mechanisms. For rare genetic disorders, identifying the causative gene and understanding what goes wrong when that gene is mutated represents the essential foundation. However, moving from genetic diagnosis to therapeutic strategy requires deeper mechanistic insights answered through biospecimen-based investigations.

Consider lysosomal storage diseases like Fabry disease, caused by mutations in the GLA gene encoding alpha-galactosidase A enzyme. While the genetic cause has been known for decades, comprehensive understanding of how deficiency of this enzyme leads to cardiac hypertrophy, renal failure, neuropathic pain, and stroke requires investigation of patient biospecimens. Plasma samples from confirmed Fabry patients reveal accumulated substrates including globotriaosylceramide (Gb3) and lyso-Gb3, documenting systemic substrate accumulation. Immune cell profiling using PBMCs enables gene expression studies and mechanistic work linking substrate accumulation to inflammatory responses and downstream fibrosis.

These mechanistic insights derived from patient biospecimens have profound implications for therapeutic strategy. If substrate accumulation alone drove all pathology, substrate reduction or enzyme replacement might provide complete solutions. However, biospecimen-based research revealing chronic inflammation, fibrosis, and secondary pathological cascades suggests that combination strategies addressing both primary substrate accumulation and downstream biology may achieve superior outcomes.

For rare diseases where genetic causes remain unknown or incompletely understood, biospecimen-based discovery research plays even more fundamental roles. Whole-exome or whole-genome sequencing from whole blood supports gene discovery and variant segregation. Complementary multi-omics can leverage plasma, scalable bulk plasma for assay development, and serum for proteomic and inflammatory marker profiling.

Target Identification and Validation

Once disease mechanisms are understood, identifying specific molecular targets amenable to therapeutic intervention requires extensive validation using patient biospecimens. A proposed target should be causally related to disease pathology, therapeutically modifiable without unacceptable toxicity, and realistically addressable through available modalities.

Biospecimen-based target validation can demonstrate that a protein is dysregulated in patient samples relative to controls, correlates with disease severity, and normalizes in response to perturbation in relevant models. For rare metabolic disorders, demonstrating that a candidate therapeutic enzyme can process accumulated substrates measurable in plasma or serum provides critical validation before advancing costly programs.

Gene therapy development for rare diseases particularly depends on biospecimen-based target validation. Programs often benchmark enzyme restoration or downstream biomarker shifts against reference distributions established using patient-derived biofluids and immune cells. When programs require higher-yield leukocyte inputs for method development or cell-based assays, human leukopaks — and when appropriate, GMP leukopaks — can support standardized workflows.

Biomarker Discovery: Creating Tools for Development and Monitoring

Biomarkers serve multiple essential functions in rare disease therapeutic development. Diagnostic biomarkers enable identification of affected patients and potentially presymptomatic screening. Prognostic biomarkers predict disease trajectory, helping identify patients most likely to benefit from early intervention. Predictive biomarkers identify which patients will respond to specific therapies, enabling precision medicine approaches. Pharmacodynamic biomarkers demonstrate that therapeutics are achieving target engagement and biological effect, de-risking development decisions by providing early evidence of mechanism-of-action before clinical benefit becomes measurable.

The pathway from biomarker discovery to clinical validation requires extensive biospecimen resources. Discovery efforts typically employ hypothesis-free approaches like proteomics, metabolomics, or transcriptomics comparing biospecimens from affected patients versus matched controls. Hundreds or thousands of candidates may emerge, requiring systematic down-selection based on biological plausibility, analytical feasibility, and validation in independent sample sets.

For Gaucher disease, biomarker development has progressed through multiple iterations. Chitotriosidase shows dramatic elevation in many Gaucher patients and is widely used for monitoring therapy response, but limitations include genetic polymorphisms causing deficiency in some populations and incomplete specificity. Biospecimen-based research has identified complementary biomarkers such as CCL18/PARC and lyso-GL1, enabling panel approaches that reduce dependence on any single marker. These programs commonly rely on standardized plasma and serum collections for cross-platform reproducibility.

Longitudinal biospecimen collections from natural history studies provide especially valuable resources for biomarker validation. Serial sampling enables assessment of whether biomarkers change consistently as disease progresses, respond appropriately to therapeutic intervention, and correlate with clinically meaningful outcomes.

Preclinical Development: Validating Models and Approaches

Animal models, patient-derived cell lines, and in vitro systems are essential tools for preclinical rare disease research, but their relevance to human disease requires validation against patient biospecimens. Researchers developing a mouse model of mucopolysaccharidosis (MPS) must demonstrate that the model recapitulates biochemical features observed in human disease, including accumulation of glycosaminoglycans and elevation of disease-associated biomarkers measurable in biofluids.

This validation depends on access to well-characterized biospecimens from confirmed patients. Biofluid benchmarks can be established using plasma and serum, while cellular readouts and immunologic pathways can be investigated using PBMCs and immune subsets such as CD3+ T cells or CD56+ NK cells when mechanistic depth is needed.

For gene therapy and cell therapy development, preclinical validation of vector design, delivery, and dosing often references human biospecimen distributions. Enzyme activity and downstream biomarker levels in treated models are compared to ranges established using specimens from healthy controls and affected patients, helping determine whether achieved levels are likely to provide therapeutic benefit.

Clinical Trial Design: Endpoints, Inclusion Criteria, and Power Calculations

Clinical trial design for rare diseases faces unique challenges including small patient populations, phenotypic heterogeneity, limited natural history data, and ethical complexities of placebo controls when potential treatments exist. Biospecimen-based research addresses many of these challenges by enabling biomarker-based patient stratification, identifying appropriate trial endpoints, and providing natural history comparators for single-arm trials.

Hunter syndrome (MPS II), an X-linked lysosomal storage disease, manifests with substantial phenotypic heterogeneity. Clinical trials enrolling heterogeneous populations often require larger sample sizes to detect treatment effects, but stratifying enrollment using genetic and biomarker profiles can reduce variability. Programs supported by robust biospecimen repositories benefit from linkable clinical context and, when applicable, genomic annotation that improves feasibility.

Endpoint selection increasingly incorporates biomarker endpoints alongside clinical measures, particularly in early-phase studies. Demonstrating reduction of accumulated substrates measurable in plasma can provide early evidence of biological effect while longer-term studies evaluate whether biomarker improvements translate into clinical benefit.

For ultra-rare diseases where fewer than one hundred affected individuals exist worldwide, traditional randomized controlled trials may be infeasible. Natural history studies with extensive biospecimen collection create external comparator cohorts, providing context for interpreting outcomes in small treated cohorts.

Regulatory Approval: Evidence Standards and Patient Access

Regulatory agencies have developed frameworks recognizing the evidentiary challenges inherent to small patient populations. Accelerated approval pathways and orphan-drug incentives create opportunities for earlier patient access, but still require robust evidence of safety and effectiveness — often supported by biomarkers when clinical endpoints are hard to measure in small trials.

Biospecimen-based biomarker evidence supports submissions by demonstrating target engagement and biological plausibility for clinical effects. For advanced modalities like gene therapies, sustained normalization of disease-relevant biomarkers measurable in blood-derived matrices can provide reassurance of durable biological effect.

Post-approval, biospecimen-based research supports therapeutic optimization and real-world evidence generation. Registries collecting biospecimens from treated patients enable long-term assessment of durability, characterization of responder subgroups, and investigation of adverse events.

Precision Medicine: Matching Patients to Therapies

As therapeutic options expand, determining which patients should receive which therapies becomes increasingly important. Enzyme replacement, substrate reduction, chaperone therapy, and gene therapy each offer distinct advantages and limitations. Companion diagnostics and predictive biomarkers derived from biospecimen-based research help match patients to approaches most likely to benefit them.

For Fabry disease, chaperone therapies that stabilize certain mutant enzyme forms provide alternatives to enzyme replacement, but effectiveness depends on the patient’s mutation. Biospecimen-based assays can evaluate chaperone responsiveness using patient-derived cells or immune readouts, supporting selection of patients likely to benefit and reducing exposure to ineffective treatment.

Pharmacogenomics increasingly informs rare disease therapeutics, but rare disease treatments require validation using biospecimens from appropriately characterized cohorts.

From Study Design to Receipt of Samples: Comprehensive Biospecimen Solutions

Supporting rare disease therapeutic development across the complete continuum requires biospecimen infrastructure built for flexibility, quality, and comprehensive annotation. Researchers often need diverse sample types including plasma, serum, PBMCs, whole blood, and specialized specimens for translational or tissue-based studies.

When programs require tissue-level investigation, samples such as skin punch biopsies can support cellular model development, fibroblast line creation, and pathway studies. Where inflammatory or joint manifestations are relevant to phenotype, matrices like synovial fluid can contribute additional translational signal for biomarker and mechanism work.

Longitudinal sample sets tracking patients over time provide insights into natural history, biomarker trajectories, and therapeutic response patterns that cross-sectional collections cannot. Matched sample sets containing multiple specimen types collected at the same timepoint from the same patient enable integrative analyses across compartments.

Sanguine’s rare disease biospecimen capabilities support therapeutic development across this complete spectrum. Our direct-to-patient collection model enables recruitment of geographically diverse cohorts across the United States, our quality management systems support sample integrity from study design to receipt of samples, and our annotation protocols capture the clinical and molecular context researchers need.

---

References

1. Health Lumen. Rare Disease Day 2025: Reflecting on a Year of Progress and the Challenges That Lie Ahead. Published February 28, 2025. Accessed December 10, 2024.
2. Delve Insight. Lysosomal Storage Disorders: A Rare Disease Overview. Published 2024. Accessed December 10, 2024.
3. Lysosomal Disease Research and Treatment Center. 2024: A Year in Review — Highlights from the LDRTC Clinical Trials and Research Unit. Newsletter. Published 2024. Accessed December 10, 2024.
4. National Institutes of Health. RFA-FD-24-024: Natural History, Clinical Outcome, and Biomarker Study. NIH Grants; 2024. Accessed December 10, 2024.
5. Kido J, Sugawara K, Nakamura K. Gene therapy for lysosomal storage diseases: current clinical trial prospects. Front Genet. 2023;14:1064924. doi:10.3389/fgene.2023.1064924
6. Rare Diseases Clinical Research Network. NIH Announces Funding to Establish and Strengthen Rare Disease Research Groups. Published October 29, 2024. Accessed December 10, 2024.